The combination of NK-mediated ADCC and cytokine signaling using TriKEs is a promising approach to clinical NK cell therapies, leading to a first-generation TriKE, GTB-3550 (CD16/IL-15/CD33) being investigated against CD33+ hematological malignancies (NCT03214666). This evidence concerns the gene CD33 and hematologic disorder.